Eidos Therapeutics Inc (NASDAQ:EIDX) was the recipient of a significant drop in short interest during the month of November. As of November 29th, there was short interest totalling 2,670,000 shares, a drop of 8.2% from the November 14th total of 2,910,000 shares. Based on an average daily trading volume, of 194,500 shares, the short-interest ratio is presently 13.7 days. Currently, 33.3% of the company’s shares are sold short.
In related news, insider Jonathan C. Fox sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $35.48, for a total transaction of $177,400.00. Also, CFO Christine Siu sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $59.75, for a total transaction of $1,195,000.00. In the last 90 days, insiders have sold 112,500 shares of company stock worth $6,273,275. Company insiders own 70.10% of the company’s stock.
Institutional investors have recently modified their holdings of the company. Redmile Group LLC lifted its position in shares of Eidos Therapeutics by 5.1% during the third quarter. Redmile Group LLC now owns 923,003 shares of the company’s stock valued at $33,200,000 after purchasing an additional 44,600 shares in the last quarter. Cormorant Asset Management LP lifted its position in shares of Eidos Therapeutics by 8.7% during the second quarter. Cormorant Asset Management LP now owns 551,921 shares of the company’s stock worth $17,154,000 after acquiring an additional 44,357 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Eidos Therapeutics by 3.3% during the 2nd quarter. Vanguard Group Inc. now owns 376,178 shares of the company’s stock worth $11,692,000 after purchasing an additional 11,857 shares in the last quarter. State Street Corp lifted its holdings in shares of Eidos Therapeutics by 0.7% in the third quarter. State Street Corp now owns 218,320 shares of the company’s stock worth $7,853,000 after buying an additional 1,523 shares in the last quarter. Finally, Northern Trust Corp lifted its stake in Eidos Therapeutics by 1.5% in the 2nd quarter. Northern Trust Corp now owns 184,115 shares of the company’s stock worth $5,723,000 after purchasing an additional 2,647 shares in the last quarter. 30.46% of the stock is owned by hedge funds and other institutional investors.
Eidos Therapeutics (NASDAQ:EIDX) last issued its earnings results on Thursday, October 31st. The company reported $0.18 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.30) by $0.48. The business had revenue of $26.69 million during the quarter. As a group, research analysts predict that Eidos Therapeutics will post -1.07 earnings per share for the current fiscal year.
A number of brokerages have recently weighed in on EIDX. ValuEngine cut shares of Eidos Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. Piper Jaffray Companies increased their target price on Eidos Therapeutics from $55.00 to $75.00 and gave the stock an “overweight” rating in a report on Tuesday, November 19th. Barclays lowered shares of Eidos Therapeutics from an “overweight” rating to an “equal weight” rating and boosted their price objective for the stock from $37.00 to $45.00 in a research report on Friday, November 1st. Roth Capital upped their target price on Eidos Therapeutics from $51.00 to $57.00 and gave the stock a “buy” rating in a report on Friday, November 1st. Finally, BTIG Research set a $56.00 price target on shares of Eidos Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, October 15th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $52.00.
About Eidos Therapeutics
Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.
Further Reading: Investing in Growth Stocks
Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.